Clinical Kidney Journal最新文献

{"title":"ERA Registry Figure of the month Expected remaining years of life for dialysis and kidney transplant patients.","authors":"Vianda S Stel, Alberto Ortiz, Anneke Kramer","doi":"10.1093/ckj/sfaf091","DOIUrl":"https://doi.org/10.1093/ckj/sfaf091","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 4","pages":"sfaf091"},"PeriodicalIF":3.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12015465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient's View on: \"Changes in body composition and handgrip strength during dapagliflozin administration in patients with chronic kidney disease\".","authors":"Takamasa Iwakura","doi":"10.1093/ckj/sfaf121","DOIUrl":"https://doi.org/10.1093/ckj/sfaf121","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 4","pages":"sfaf121"},"PeriodicalIF":3.9,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute kidney injury does not explain sex differences in kidney replacement therapy initiation or death amongst individuals with chronic kidney disease reported to the UK Renal Registry.","authors":"Takahiro Tsuji, Anna Casula, Laurie Tomlinson, Dorothea Nitsch, Barnaby Hole","doi":"10.1093/ckj/sfaf105","DOIUrl":"https://doi.org/10.1093/ckj/sfaf105","url":null,"abstract":"<p><strong>Background: </strong>Why more males than females start kidney replacement therapy (KRT) is incompletely understood. Acute kidney injury (AKI) is a possible factor underlying sex differences in chronic kidney disease (CKD) progression, but previous studies regarding this have been inconclusive. We investigated sex differences in the association between AKI and CKD progression in UK nephrology care.</p><p><strong>Methods: </strong>This cohort study uses UK Renal Registry data. Adults with CKD stages 4/5 in 14 nephrology centres in England were followed from January 2018 to December 2021. We compared their baseline characteristics by sex and calculated cause specific hazard ratio (HR) for outcomes: time to AKI stage 2/3 (AKI2/3), initiation of chronic KRT and death by all causes.</p><p><strong>Results: </strong>A total of 15 547 patients were included. Fewer females (43.8%) were seen in renal centres than males (56.2%). During follow-up, 3909 (25.1%) AKI2/3 episodes, 3510 (22.6%) KRT initiations, and 7293 (46.9%) deaths were observed. Males were more likely than females to experience each outcome: AKI2/3 [adjusted HR 1.39, 95% confidence interval (CI) 1.31-1.49], KRT initiation (adjusted HR 1.51, 95% CI 1.39-1.65) and death (adjusted HR 1.11, 95% CI 1.05-1.16). Adjustment for AKI2/3 did not change the association between being male and the higher risk of KRT initiation.</p><p><strong>Conclusion: </strong>Being male was associated with a higher risk of AKI2/3, KRT initiation and death. Fewer females appeared in nephrology care data than expected from population CKD prevalence. However, no evidence was found to support the hypothesis that AKI2/3 explains the higher KRT initiation rates seen amongst males.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 5","pages":"sfaf105"},"PeriodicalIF":3.9,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor-associated membranous nephropathy.","authors":"Maxime Teisseyre, Alexandre Destere, Marion Cremoni, Sonia Boyer-Suavet, Alexandre Karamé, Léa Corlu, Gabrielle Duneau, Paule Poirier, Siriane Lefevre, Kévin Zorzi, Céline Fernandez, Vesna Brglez, Sylvia Benzaken, Guillaume Favre, Milou-Daniel Drici, Vincent L M Esnault, Sylvain Benito, Barbara Seitz-Polski","doi":"10.1093/ckj/sfaf113","DOIUrl":"https://doi.org/10.1093/ckj/sfaf113","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 5","pages":"sfaf113"},"PeriodicalIF":3.9,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-related glomerular loss in patients with IgA nephropathy.","authors":"Hirokazu Marumoto, Nobuo Tsuboi, Takaya Sasaki, Yusuke Okabayashi, Kotaro Haruhara, Go Kanzaki, Takashi Yokoo","doi":"10.1093/ckj/sfaf111","DOIUrl":"https://doi.org/10.1093/ckj/sfaf111","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 5","pages":"sfaf111"},"PeriodicalIF":3.9,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of aspiration during general anaesthesia in patients on glucagon-like peptide-1 (GLP-1) receptor agonists: implications for patients on the kidney transplant waiting list.","authors":"Imeshi Wijetunga, Thomas Clarke, Alexander Woywodt, Madelena Stauss","doi":"10.1093/ckj/sfaf110","DOIUrl":"https://doi.org/10.1093/ckj/sfaf110","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 5","pages":"sfaf110"},"PeriodicalIF":3.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting IL-6 in antibody-mediated kidney transplant rejection.","authors":"Mehmet Kanbay, Berk Mizrak, Sidar Copur, Ezgi N Alper, Sebahat Akgul, Alberto Ortiz, Caner Susal","doi":"10.1093/ckj/sfaf108","DOIUrl":"https://doi.org/10.1093/ckj/sfaf108","url":null,"abstract":"<p><p>Interleukin (IL)-6 is a major pro-inflammatory cytokine and central regulator of innate and adaptive immune responses. Clinical trials testing antibodies against IL-6 or its receptors have demonstrated its involvement in the pathogenesis of several autoimmune and inflammatory disorders and in the systemic inflammation and anemia associated to kidney failure and also in kidney allograft rejection. Additionally, the anti-IL-6 receptor antibody tocilizumab and the anti-IL-6 antibody clazakizumab have been studied for the treatment of naïve as well as resistant antibody-mediated kidney allograft rejection with mixed results in observational studies and early clinical development. Following promising results with a clazakizumab in a phase 2 placebo-controlled trial, a large phase 3 trial (IMAGINE) was terminated in 2024 for futility at interim analysis. Investigator-initiated clinical development continues in a smaller phase 3 trial testing tocilizumab (INTERCEPT). In this viewpoint article, we evaluate the pathophysiology of IL-6 in antibody-mediated kidney allograft rejection along with the current status of the clinical development of IL-6 targeting therapies for antibody-mediated kidney allograft rejection episodes within the wider frame of IL-6 targeting therapies in kidney failure that are considered the major causes of graft loss in kidney transplantation.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 5","pages":"sfaf108"},"PeriodicalIF":3.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation and evaluation of a smartphone-based application for continuous ambulatory peritoneal dialysis (CAPD) patients: a prospective feasibility cohort study and collaborative effort of patients and the peritoneal dialysis team.","authors":"Caroline W H de Fijter, Wiard Jorritsma, Len Rutten, Asja Vermeulen, Danielle Zuijderduijn","doi":"10.1093/ckj/sfaf102","DOIUrl":"https://doi.org/10.1093/ckj/sfaf102","url":null,"abstract":"<p><strong>Background: </strong>eHealth technology bridging home and hospital care was shown to allow efficient use of healthcare resources in automated peritoneal dialysis (APD). Data on eHealth applications in patients on continuous ambulatory PD (CAPD) are scarce. We evaluated implementation of a smartphone app enabling remote patient care in CAPD.</p><p><strong>Methods: </strong>In this prospective observational cohort study, all PD patients were informed and could choose whether or not to use the app. A confounder-controlled analysis was performed to compare outcomes between users and non-users. App users rated experienced support, feeling of safety and need for interim hospital visits. Renal nurses participated in a structured interview.</p><p><strong>Results: </strong>A total of 36 of 72 participating patients used the app. The app was associated with a 90% decrease in hospital admission days [95% confidence interval (CI) 51-98] and a 62% decrease in hospital admissions (95% CI 21-83). There was no clear effect on the number of emergency room visits, consultations and patient-reported outcomes. Patient's satisfaction with the app was high (mean rating 4.8 on a 1-5 scale), experiencing a decrease in the need for hospital visits and almost all felt safer. Nurses appreciated a time-efficient improvement in quality of patient-focused care.</p><p><strong>Conclusion: </strong>Implementation of the app maintained and even increased interaction between patients and the PD team time-efficiently. The app was associated with fewer hospitalization days and was rated positively by patients and nurses. The safe sharing of photos feature reduced interim hospital visits, presumably lowering the carbon footprint. We embedded the app in our practice as a form of value-based healthcare.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 5","pages":"sfaf102"},"PeriodicalIF":3.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary peptide signature distinguishes autosomal recessive polycystic kidney disease from other causes of chronic kidney disease.","authors":"Kathrin Burgmaier, Bénédicte Buffin-Meyer, Julie Klein, Brian Becknell, Daryl McLeod, Jan Boeckhaus, Oliver Gross, Claudia Dafinger, Justyna Siwy, Stéphane Decramer, Franz Schaefer, Max C Liebau, Joost P Schanstra","doi":"10.1093/ckj/sfaf093","DOIUrl":"https://doi.org/10.1093/ckj/sfaf093","url":null,"abstract":"<p><strong>Background: </strong>The diagnosis of autosomal recessive polycystic kidney disease (ARPKD) can be hampered by its pronounced phenotypic variability and ARPKD-mimicking phenocopies. Here, for the first time we specifically studied the urinary peptidome of patients with ARPKD with the aim of distinguishing ARPKD from other causes of chronic kidney disease (CKD).</p><p><strong>Methods: </strong>Fifty-eight urine samples from patients with ARPKD, 662 urine samples from paediatric patients with CKD with various other CKD aetiologies and 45 samples from healthy children were included. The urinary peptidome was analysed by capillary electrophoresis/mass spectrometry.</p><p><strong>Results: </strong>A 77-peptide signature specific for ARPKD was identified. Application of this signature in a matched random validation set of 19 samples of patients with ARPKD, 23 samples from patients with other CKD and 21 samples from healthy individuals led to a sensitivity of 84.2% [95% confidence interval (CI) 60.4-96.6], a specificity of 100% (95% CI 92.0-100%) and an area under the receiver operating characteristics curve (AUC) of 0.994 (95% CI 0.93-1.00). The 77-peptide signature displayed a specificity of 76.1% (95% CI 72.4-79.5) and an AUC of 0.88 (95% CI 0.85-0.90) in 591 samples from non-matched children with various CKD aetiologies. The signature was primarily (83%) composed of collagen fragments indicating structural damage. Of the remaining peptides, five originated from proteins known to bind to calcium potentially linking the current work to defaults in calcium signalling in polycystic disease.</p><p><strong>Conclusions: </strong>We determined a urinary peptide signature that identifies paediatric patients with ARPKD with high precision among a population of children with CKD. Knowledge of the identity of the underlying peptides offers a novel starting point for discussion of possible pathophysiological processes involved in ARPKD.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 5","pages":"sfaf093"},"PeriodicalIF":3.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic anticoagulation in patients with nephrotic syndrome in the Cure Glomerulonephropathy (CureGN) cohort.","authors":"Blanca Tarragón, Heedeok Han, Mariela Navarro-Torres, Pietro Canetta, Benjamin Wooden, Vimal K Derebail, Dorey Glenn, Amy Mottl, David Massicotte-Azarniouch, Bryce Kerlin, Michelle Hladunewich, Gaia Coppock, Michelle Rheault, Laura H Mariani, Andrew Bomback","doi":"10.1093/ckj/sfaf104","DOIUrl":"https://doi.org/10.1093/ckj/sfaf104","url":null,"abstract":"<p><strong>Background: </strong>Adult and paediatric patients with nephrotic syndrome (NS) due to different glomerular diseases are at a higher risk of thromboembolic events than the general population, but the use of prophylactic anticoagulation (PAC) among them has not been well described. Although the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines offer an algorithm to guide the management of PAC, the degree of implementation in practice is unknown.</p><p><strong>Methods: </strong>We evaluated thromboprophylaxis management in patients with NS secondary to membranous nephropathy, focal segmental glomerulosclerosis, minimal change disease and C1q nephropathy enrolled in the Cure Glomerulonephropathy (CureGN) cohort study (diagnosed 2010-2023) and assessed the concordance or discordance with the 2021 KDIGO guidelines practice points in adults. We also analysed thrombotic and bleeding events.</p><p><strong>Results: </strong>Among 374 adult and 263 paediatric NS episodes, PAC was prescribed in 21 (6%) and 11 (4%) episodes, respectively. In adults, PAC prescription was associated with a history of prior thrombosis, lower serum albumin and higher proteinuria, with coumarins and direct oral anticoagulants (DOACs) being equally the most prescribed agents. In adults, anticoagulation management was concordant with guidelines in 180 (48%) episodes, discordant in 59 (16%) and indeterminate in 135 (36%). Most (92%) guideline-discordant episodes were cases with a high thrombotic risk and low bleeding risk where PAC was not prescribed. In children, PAC prescription was associated with lower albuminaemia and worse kidney function, with heparins being the only agent used. Thrombotic events occurred during 5 (1.3%) and 4 (1.5%) of all adult and paediatric NS episodes, respectively.</p><p><strong>Conclusions: </strong>PAC was used more conservatively than guidelines suggest and was mainly driven by hypoalbuminaemia severity in both adults and children. Although not included in the guidelines practice points, DOACs were used as often as coumarins in adults.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 5","pages":"sfaf104"},"PeriodicalIF":3.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}